Literature DB >> 16530171

Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.

Hiroaki Yamada1, Naohito Shimoyama, Ichiro Sora, George R Uhl, Yasuichiro Fukuda, Hideshige Moriya, Megumi Shimoyama.   

Abstract

Previous studies have demonstrated the virtual lack of analgesia in mu opioid receptor knockout mice after systemic administration of morphine. Thus, it has been suggested that analgesic actions of morphine are produced via the mu opioid receptor, despite its ability to bind to kappa and delta receptors in vitro. However, it is not clear whether the results of these studies reflect the effect of morphine in the spinal cord. In the present study, we report study of the analgesic actions of spinally-administered morphine and other opioid receptor agonists in mu opioid receptor knockout and wild type mice. Morphine produced a dose-dependent antinociceptive effect in the tail flick test in the knockout mice, although higher doses were needed to produce antinociception than in wild type mice. The antinociceptive effect of morphine was completely blocked by naloxone (a non-selective opioid antagonist) and nor-binaltorphimine (nor-BNI, a selective kappa-opioid receptor antagonist), but not by naltrindole (a selective delta-opioid receptor antagonist). U-50,488H (a selective kappa-opioid receptor agonist) also produced a dose-dependent antinociceptive effect in knockout mice but presented lower analgesic potency in knockout mice than in wild type mice. Analgesic effects of [d-Pen2,d-Pen5]enkephalin (DPDPE, a selective delta-opioid receptor agonist) were observed in wild type mice but abolished in knockout mice. SNC80 (a selective delta-opioid receptor agonist) was not antinociceptive even in wild type mice. The present study demonstrated that morphine can produce thermal antinociception via the kappa opioid receptor in the spinal cord in the absence of the mu opioid receptor. Lower potency of U50,488H in mu opioid receptor knockout mice suggests interaction between kappa and mu opioid receptors at the spinal level.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530171     DOI: 10.1016/j.brainres.2006.01.095

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  19 in total

Review 1.  Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins.

Authors:  Yingxue Li; Mark R Lefever; Dhanasekaran Muthu; Jean M Bidlack; Edward J Bilsky; Robin Polt
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

3.  Nor-Binaltorphimine Blocks the Adverse Effects of Morphine after Spinal Cord Injury.

Authors:  Miriam Aceves; Eric A Bancroft; Alejandro R Aceves; Michelle A Hook
Journal:  J Neurotrauma       Date:  2016-11-04       Impact factor: 5.269

Review 4.  Current research on opioid receptor function.

Authors:  Yuan Feng; Xiaozhou He; Yilin Yang; Dongman Chao; Lawrence H Lazarus; Ying Xia
Journal:  Curr Drug Targets       Date:  2012-02       Impact factor: 3.465

5.  OPRM1, OPRK1, and COMT genetic polymorphisms associated with opioid effects on experimental pain: a randomized, double-blind, placebo-controlled study.

Authors:  Kwo Wei David Ho; Margaret R Wallace; Roland Staud; Roger B Fillingim
Journal:  Pharmacogenomics J       Date:  2019-12-06       Impact factor: 3.550

6.  Drug response profiles to experimental pain are opioid and pain modality specific.

Authors:  Lindsay L Kindler; Kimberly T Sibille; Toni L Glover; Roland Staud; Joseph L Riley; Roger B Fillingim
Journal:  J Pain       Date:  2010-12-13       Impact factor: 5.820

7.  Co-activation of μ- and δ-opioid receptors elicits tolerance to morphine-induced ventilatory depression via generation of peroxynitrite.

Authors:  Alex P Young; Ryan B Gruber; Joe F Discala; Walter J May; Dylan McLaughlin; Lisa A Palmer; Stephen J Lewis
Journal:  Respir Physiol Neurobiol       Date:  2013-03-05       Impact factor: 1.931

8.  Differential involvement of opioidergic and serotonergic systems in the antinociceptive activity of N-arachidonoyl-phenolamine (AM404) in the rat: comparison with paracetamol.

Authors:  Valentina Ruggieri; Giovanni Vitale; Luigi Alberto Pini; Maurizio Sandrini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-11       Impact factor: 3.000

9.  Cannabinoid transmission in the prelimbic cortex bidirectionally controls opiate reward and aversion signaling through dissociable kappa versus μ-opiate receptor dependent mechanisms.

Authors:  Tasha Ahmad; Nicole M Lauzon; Xavier de Jaeger; Steven R Laviolette
Journal:  J Neurosci       Date:  2013-09-25       Impact factor: 6.167

10.  Opiate-agonist induced taste aversion learning in the Fischer 344 and Lewis inbred rat strains: evidence for differential mu opioid receptor activation.

Authors:  Catherine M Davis; Kenner C Rice; Anthony L Riley
Journal:  Pharmacol Biochem Behav       Date:  2009-06-07       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.